Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V Action Heats Up On Hill With House Hearings In February

This article was originally published in The Pink Sheet Daily

Executive Summary

An Energy and Commerce subcommittee will discuss the FDA and industry agreement on prescription drug user fees with FDA Commissioner Margaret Hamburg Feb. 1. Drug shortages will be part of the deliberations Feb. 7 when CDER Director Janet Woodcock goes before the panel to make the case for user fees on generic drugs and biosimilars.

Advertisement

Related Content

Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch
“Comprehensive” Drug Shortage Mitigation Bill Under Development In House
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay
FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
FDA Wants Authority To Enforce Track-And-Trace System For Drugs
PDUFA Commitment Letter Formalizes REMS Standardization Schedule
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
FDA Receives Assurances That PDUFA Remains Priority on Capitol Hill

Topics

Advertisement
UsernamePublicRestriction

Register

PS073255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel